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Aim: Assessment of the association of an acute motor axonal neuropathy with a squamous
cell anal carcinoma.
Background: Paraneoplastic neurologic syndromes are not a direct consequence of neither
primary tumor nor its metastasis. They often parallel the course of the malignancy but may
be the presenting sign of an occult cancer. Sometimes it is very difﬁcult to distinguish if it
is a paraneoplastic syndrome or just a coincidence.
Materials and methods: We report a 60-year-old man that presented with an acute motor
deﬁcit of the four limbs. Clinical examination found a pure and severe motor deﬁcit in
the four limbs. No sensory abnormality was found and all motor nerves were unexcitable.
Electromyography suggested the diagnosis of acute motor axonal neuropathy (AMAN). Four
months after developing the AMAN, blood in the stool revealed anal carcinoma. The patient
was treated with concurrent chemoradiotherapy. Radiation was given to the tumor and to
the pelvis, including inguinal nodes, over a ﬁve-week period plus ﬂuorouracil and mito-
mycin. We investigated the presence of antiganglioside antibodies as studies suggest that
carcinomas can express antigens shared with Schwann cells.
Results: Anti-GM1 IgG antibodies were detected by an enzyme-linked immunosorbent assay
method. Other antibodies, including antinuclear nucleoprotein antibody (anti-Hu), anti-Tr,
anti-Ri, anti-CV2, anti-amphiphysin and anti-Yo, were negative. Clinical improvement of
the motor state was observed at the fourth week of oncologic treatment.
Conclusion: The presence of anti-GM1 IgG antibodies and the clinical improvement of the
motor state after concurrent chemoradiotherapy lead us to believe there is an associationbetween anal carcinoma and this severe impairment.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
z.o.o. All rights reserved.
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. Background
araneoplastic syndromes occur in about 1% of all active
ancers.1 The clinical course of these syndromes sometimes
orrelateswith theunderlyingmalignancy,whichmay suggest
n ascertain paraneoplastic etiology. However, in some other
ases both the paraneoplastic syndrome and the tumor follow
ndependent courses. In either situation it is essential to con-
ider their potential existence for they may indicate the ﬁrst
ign of a malignant process. This will contribute to their early
etection in a curable stage and their use as clinical tumor
arkers of early recurrences in treated patients. Squamous
ell carcinoma is not a common histological type associated
ith paraneoplastic neurologic syndromes (PNS). Few cases
re described in the literature.2,3 These disorders often appear
o have an autoimmune pathogenesis, as suggested by the
resence of autoantibodies directed against both neurons and
ancer cells.4 We present the case of one patient with an acute
otor neuropathy associated with squamous cell anal carci-
oma. The association described here has not been reported
efore.
. Case report
60-year-old man was admitted to the hospital for an acute
otor deﬁcit of the four limbs. Clinical examination found a
ure and severe motor deﬁcit in the four limbs. No sensory
bnormality was found. Deep tendon reﬂexes were abolished.
lectromyography suggested the diagnosis of acute motor
xonal neuropathy (AMAN).Allmotornerveswereunexcitable
Fig. 1 – Spontaneous activity in dene
Fig. 2 – Ulnar motor nerve conduction velocity. ADM: a
ig. 3 – Magnetic resonance imaging scan of the pelvis showing:
3mm×33mm in diameter, (b) perirectal lymph node 11mm iniotherapy 1 6 ( 2 0 1 1 ) 54–57 55
(Fig. 1), except for the right ulnar nerve (Fig. 2), which evoked
a compound muscle action potential reduced in amplitude
and conducted at 34.5m/s with F wave latencies not delayed.
Sensitive nerve conductions were normal. Needle electromyo-
graphy showed severe acute diffuse denervation. The patient
was treated with intravenous inmunoglobulin. Despite the
treatment, the patient continued to have profound ascend-
ing muscle weakness, eventually involving the bulbar and
facial muscles. Due to respiratory distress and respiratory
muscle weakness, the patient required mechanical ventila-
tion. Five sessions with plasma exchanges were performed
without any signs of improvement. The patient continued to
stay in the Intensive Care Unit. Once the patient was able
to sustain spontaneous breathing, he was taken to the Neu-
rology Department. Four months after developing the AMAN,
blood in the stool revealed anal carcinoma. The anoscopy and
biopsy showed an anal squamous cell carcinoma. The tumor
was classiﬁed as stage 3 (Fig. 3).
Routine laboratory data showed no abnormalities. Human
papillomavirus DNA type determination was positive. Campy-
lobacter jejuni, cytomegalovirus and Epstein-Barr virus
serology were negative. CEA were normal. Cerebrospinal
ﬂuid analysis did not show any abnormalities. Anti-GM1 IgG
antibodies were detected by an enzyme-linked immunosor-
bent assay method. Other antibodies, including antinuclear
nucleoprotein antibody (anti-Hu), anti-Tr, anti-Ri, anti-CV2,
anti-amphiphysin and anti-Yo, were negative. We analyzed
the antibodies in serum by indirect immunoﬂuorescence. The
case was discussed in the multidisciplinary Gastrointestinal
Tumor Board of our Center and the recommendation was to
treat anal carcinoma by delivering concurrent chemoradio-
therapy in order to achieve an adequate loco-regional control
rvated anterior tibialis muscle.
bductor digiti minimi; Ab: abduction; Elb: elbow.
(a) Solid mass measuring 63mm in length and
diameter, and (c) invasion of the internal anal sphinter.
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and motor improvement. Radiation was given to the tumor
and to the pelvis including inguinal nodes, in 25 fractions
over a ﬁve-week period plus ﬂuorouracil and mitomycin. The
chemoradiotherapy was well tolerated. Clinical improvement
of the motor state was observed at the fourth week of the
oncologic treatment. Unfortunately, three days after ﬁnishing
the chemoradiotherapy the patient died due to an episode of
bronchoaspiration.
3. Discussion
The patient developed ascending paralysis, progressing to
tetraplegia within two weeks. No history of intoxication or
porphyria was apparent. The main clinical symptoms of the
patient were characterized by acute motor deﬁcit of the four
extremities without sensory affectation. The motor impair-
ment was apparent four months before the detection of anal
carcinoma. We detected an autoantibody against the ganglio-
side in the serum of the patient. Therefore, it was possible that
the patient had paraneoplastic motor neuropathy. The pres-
ence of this severe impairment and anal carcinoma are unique
clinical features in this patient.
In parts of China, Japan, India, and central part of South
America, the underlying abnormality is more commonly
an acute motor axonal neuropathy, in which the primary
autoimmune attack is directed against the axon. Patients
with AMAN are more likely than other GBS patients to
have IgG antiganglioside GM1 antibodies.5 Pathologically, one
can observe motor axonal degeneration with antibody medi-
ated attacks of motor nerve and nodes of Ranvier.6 Elevated
titers of serum anti-ganglioside antibodies are characteristic
of Guillain-Barré syndrome (GBS). Complement system has
been shown to be involved in the anti-ganglioside antibody-
mediated pathogenetic mechanisms. Some GBS patients have
antibodies speciﬁc to a conformational epitope formed by
two different gangliosides. Among such anti-ganglioside com-
plex antibodies, anti-GD1a/GD1b IgG antibodies are shown
to be associated with severe GBS requiring artiﬁcial venti-
lation. In contrast, antibodies highly speciﬁc to GD1b are
associated with GBS with ataxia. Sensory ataxic neuropathy
is induced by sensitization of rabbits with GD1b. An apo-
ptotic mechanism has recently been shown to be involved
in the pathogenesis of this animal model. Most of the
patients with Fisher syndrome have anti-GQ1b IgG antibodies.
Recent investigation on anti-ganglioside complex antibody
showed that antibodies in Fisher syndrome can be subdivided
into three groups; GQ1b-speciﬁc, GQ1b/GM1-speciﬁc, and
GQ1b/GD1a-speciﬁc.
Research on antibodies to gangliosides and ganglioside
complexes will provide a clue to develop a novel treatment
of GBS.7 Hadden et al. performed an electrophysiological
and serological testing within 15 days of symptom onset on
369 patients with GBS enrolled in a trial comparing plasma
exchange, intravenous immunoglobulin, and both. Antigan-
glioside GM1 antibodies were present in a higher proportion
of patients with axonal physiology or inexcitable nerves than
other patients. Pure motor GBS patients were more likely
than other GBS patients to have IgG antiganglioside GM1
antibodies.8diotherapy 1 6 ( 2 0 1 1 ) 54–57
PNS may indicate the ﬁrst sign of a malignant process.
This will contribute to the early detection of tumors and their
use as clinical tumor markers. In more than 50% of cases,
they precede the ﬁnding of the underlying neoplasm.9 PNS
have been linked to the production of antibodies stimulated
by tumor antigen, consequently attacking neuronal antigen.
Anti-Hu antibodies in small-cell lung carcinoma damage the
nuclei of peripheral nervous system neurons and are asso-
ciated with subacute sensory neuropathy; anti-Yo antibodies
in ovarian cancers damage Purkinje cells. The presence of
speciﬁc Hodgkin’s Disease associated with paraneoplastic
cerebellar degeneration autoantibodies against Purkinje cells,
called Anti-Tr, has been reported.10,11 De Toni et al. described
two patients with progressive neuropathy and lung cancer
in whom gangliosides may represent the oncoantigens. One
patient had motor neuropathy, high titers of IgG1 and IgG3
to GD1a and GM1; the other presented with Miller–Fisher-
like syndrome and IgG3 activity to disialo-gangliosides. In
both cases, responses and stabilization of neuropathy were
accomplished by tumor treatment. Ganglioside expression on
neoplastic tissue may elicit autoimmune responses, which
also target neural structures.12 PNS include abnormalities in
the peripheral or central nervous system, in patients with
malignancy, and result from mechanisms other than metasta-
sis, metabolic or nutritional deﬁcits, infections, coagulopathy
or side effects of chemotherapy.13–15
The prevalence of PNS ranges from 0.5 to 2.0% and is
highest in patients with small cell lung cancer or gyne-
cologic tumors.16 Other tumors associated with PNS are
breast cancer and Hodgkin’s Lymphoma.17 Although squa-
mous cell carcinoma is not a common histological type
associated with PNS, some cases have been described in
the literature.2,3 Central nervous system manifestations
of a PNS comprise limbic encephalitis, cerebellar degen-
eration with dizziness, vertigo, limb and trunk ataxia,
dysarthria, dysphagia, nystagmus, oscillopsia, vertigo, or
diplopia, encephalomyelitis, retinal syndrome, opsoclonus,
motor-neuron disease, or stiff-person syndrome.15,18 Periph-
eral nervous system manifestations of a PNS comprise
polyneuropathy, polymyositis/dermatomyositis, necrotizing
myopathy, endocrine myopathy, neuromyotonia, myasthenia
gravis, or Lambert–Eaton syndrome.16 Generally, PNS can
occur without antineuronal antibodies and antineuronal
antibodies without PNS.13 We speculate that Anti-GM1 IgG
antibodies are mediated by the tumor, as studies suggest
that carcinomas can express antigens shared with Schwann
cells.19,20 IgGs are readily absorbed from the nerve terminals
for retrograde transport to the soma and transneuronal
uptake by the neuropils in the spinal grey.21 Prompt inter-
nalization of IgGs may cause damage and dysfunction of not
only the axon but also the soma.
Despite the lack of clinical improvement of AMAN for four
months, we thought it could improve if we treated the tumor.
Shoulder and pelvis movements were observed the last week
of the chemoradiotherapy treatment. Despite the good toler-
ance of the oncologic treatment, the patient died three days
after ﬁnishing the treatment due to an episode of bronchoaspi-
ration. The possibility could not completely be ruled out that
the presence of the IgG antiganglioside GM1 antibody was
incidental in this patient. However, the association between
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he autoantibody and the tumor seems to be possible by sev-
ral reasons: response and stabilization of neuropathy were
ccomplished by tumor treatment and the fact that there was
o antecedent of infection that could explain the presence
f antiganglioside antibodies produced by the mechanism of
olecular mimicry between gangliosides and lipopolysaccha-
ides of infectious pathogens.
We agree with Vallat et al.22 that looking for the presence of
n intercurrent condition, such as an underlying carcinoma,
n front of acute polyneuritis should be the rule. It would help
o deliver the adequate treatment in early stages for improv-
ng both the tumor control and the acute polyneuritis (pure
ensitive, pure motor or sensorimotor).
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